newsfilter
← Latest News
GlobeNewswire·

eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial

SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient with non-small cell lung ca